报告人：梁锦荣（Kam W. Leong）教授（美国工程院院士、Biomaterials主编）
题目：Nanotherapeutics: Critical Delivery Barriers and Engineering Strategies
Advances in genomics and systems biology have identified many nucleic acid-based therapeutics such as DNA, siRNA, mRNA and aptamers that can target diseases at the molecular level. The future of genetic medicine hinges on the successful intracellular delivery of these nucleic acid-based therapeutics. I will discuss our past effort on understanding the rate barriers in nonviral gene transfer using quantum dot-FRET (QD-FRET) technology. I will also present our recent effort on various nanotherapeutic applications.
题目：Biomaterial Strategies to Modulate Inflammation
Many chronic disabling diseases such as rheumatoid arthritis, psoriasis, multiple sclerosis and systemic lupus erythematosus are increasingly linked to inappropriate and chronic activation of inflammatory cells. A central event in the pathogenesis of these diseases appears to be an aberrant activation of innate immune sensors, most prominently the Pattern Recognition Receptors (PRRs), by nucleic acids that are released from dead and dying cells. Moreover, such extracellular nucleic acids have also been implicated in acute thrombotic disorders such as heart attack, traumatic injury, and stroke in activating the contact pathway of coagulation. In this presentation, I will discuss the application of nucleic acid-binding polymers in the configuration of either soluble or immobilized polycation to scavenge these pathogenic nucleic acids as a molecular strategy to combat inflammation.
Kam W. Leong is the Samuel Y. Sheng Professor of Biomedical Engineering at Columbia University. He received his PhD in Chemical Engineering from the University of Pennsylvania. After serving as a faculty in the Department of Biomedical Engineering at The Johns Hopkins School of Medicine for almost 20 years, he moved to Duke University in 2006 to study the interactions of cells with nanostructures for therapeutic applications. After moving to Columbia University in September 2014, he continues to work on nanoparticle-mediated nonviral gene delivery and immunotherapy. He also works on the application of nanostructured biomaterials for regenerative medicine, particularly on understanding cell-topography interactions and on the application of nonviral vectors for direct cellular reprogramming and genome editing. He has published ~330 peer-reviewed research manus with >39,000 citations, an h-index of 103, and holds more than 50 issued patents. His work has been recognized by a Young Investigator Research Achievement Award of the Controlled Release Society, Distinguished Scientist Award of the International Journal of Nanomedicine, Clemson Award for Applied Research of the Society for Biomaterials, and Life Time Achievement Award of the Chinese American Society of Nanomedicine and Nanotechnology. He is the Editor-in-Chief of Biomaterials, a member of the USA National Academy of Inventors, and a member of the USA National Academy of Engineering.